Sabra Health Care price target raised to $20 from $18 at Truist

Truist raised the firm’s price target on Sabra Health Care (SBRA) to $20 from $18 and keeps a Hold rating on the shares. The firm notes Sabra Health Care has a strong balance sheet, and the stock has performed well year-to-date. That said, it is not as low levered as several peers and, despite trading near the high end of its 10-year stock valuation range, Truist estimates its current cost of equity leaves relatively little room for immediate earnings accretion on acquisitions in what it thinks is an attractive/competitive healthcare REIT sector.